- Home
- PLCE vs VERU Comparison
PLCE vs VERU Comparison
Compare PLCE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- VERU
- Stock Information
- Founded
- PLCE 1969
- VERU 1971
- Country
- PLCE United States
- VERU United States
- Employees
- PLCE N/A
- VERU N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- PLCE Consumer Discretionary
- VERU Health Care
- Exchange
- PLCE Nasdaq
- VERU Nasdaq
- Market Cap
- PLCE 76.8M
- VERU 76.9M
- IPO Year
- PLCE 1997
- VERU 1990
- Fundamental
- Price
- PLCE $5.71
- VERU $0.53
- Analyst Decision
- PLCE Hold
- VERU Strong Buy
- Analyst Count
- PLCE 3
- VERU 3
- Target Price
- PLCE $8.33
- VERU $4.33
- AVG Volume (30 Days)
- PLCE 519.2K
- VERU 2.2M
- Earning Date
- PLCE 04-11-2025
- VERU 05-07-2025
- Dividend Yield
- PLCE N/A
- VERU N/A
- EPS Growth
- PLCE N/A
- VERU N/A
- EPS
- PLCE N/A
- VERU N/A
- Revenue
- PLCE $1,386,269,000.00
- VERU $16,886,419.00
- Revenue This Year
- PLCE N/A
- VERU N/A
- Revenue Next Year
- PLCE N/A
- VERU N/A
- P/E Ratio
- PLCE N/A
- VERU N/A
- Revenue Growth
- PLCE N/A
- VERU 22.46
- 52 Week Low
- PLCE $4.77
- VERU $0.45
- 52 Week High
- PLCE $19.74
- VERU $1.75
- Technical
- Relative Strength Index (RSI)
- PLCE 35.07
- VERU 48.10
- Support Level
- PLCE $5.32
- VERU $0.50
- Resistance Level
- PLCE $6.09
- VERU $0.58
- Average True Range (ATR)
- PLCE 0.92
- VERU 0.07
- MACD
- PLCE -0.20
- VERU -0.00
- Stochastic Oscillator
- PLCE 9.22
- VERU 16.67
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.